Source-grounded facts extracted from KYNTRA BIO, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
KYNTRA BIO, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-12 meeting.
“The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the Kyntra Bio board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2026: 2,712,825 shares of Common Stock voted for, 14,392 against, and 7,461 abstaining.”
KYNTRA BIO, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-12 meeting.
“The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement filed on April 27, 2026: 1,242,005 shares of Common Stock voted for, 23,606 against, 24,639 abstaining, and 1,444,428 broker non-votes.”
KYNTRA BIO, INC. shareholders approved Election of Class III director nominee Michael Kauffman, M.D., Ph.D. at the 2026-06-12 meeting.
“The Class III director nominee, Michael Kauffman, M.D., Ph.D., was elected to hold office until the Company’s 2029 annual meeting of stockholders. The director received 96.04% of the shares voting: 1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes.”
KYNTRA BIO, INC. reported first quarter 2026 results: revenue $3.7 million, net income $15.1 million, or $3.74 net loss per basic and diluted share, EPS $3.74 net loss per basic and diluted share.
“Total revenue from continuing operations for the first quarter of 2026 was $3.7 million, as compared to $2.7 million for the first quarter of 2025. • Net loss from continuing operations for the first quarter of 2026 was $15.1 million, or $3.74 net loss per basic and diluted share, compared to a net loss of $16.8 million, or $4.15 net loss per basic and diluted share, one year ago.”
KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(b)(3)(A)).
“April 2, 2026, Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying us that the Company no longer complies with the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue for the most recently completed fiscal year (or two of the last three most recently completed fiscal years) per Listing Rule 5450(b)(3)(A). This is due to the revenue of FibroGen International being presented as held for sale (in discontinued operations) in 2024 and 2025. The Comp”
KYNTRA BIO, INC.: Amended bylaws solely to update the title to reflect the company's new name, Kyntra Bio, Inc (effective 2026-01-07).
“The Board also approved the amendment of the Company’s Bylaws, effective at 4:30 p.m. Eastern Time on January 7, 2026, solely to update the title of the Bylaws to reflect the Company’s new name, Kyntra Bio, Inc.”
KYNTRA BIO, INC.: Amended certificate of incorporation to change company name from FibroGen, Inc. to Kyntra Bio, Inc (effective 2026-01-07).
“On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.”
KYNTRA BIO, INC. completed a disposition involving AstraZeneca Treasury Limited for approximately $220 million (closed 2025-08-29).
“sold all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, for approximately $220 million”
KYNTRA BIO, INC.: Effected a 1-for-25 reverse stock split of common stock via amendment to the certificate of incorporation (effective 2025-06-16).
“On June 10, 2025, FibroGen, Inc. (“FibroGen” or the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware for a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company's Common Stock (the “Common Stock” ). The Certificate of Amendment will take effect, as of 5:00 p.m. Eastern Time on June 16, 2025 (the “Effective Time”).”
Aoife Brennan resigned as Director at KYNTRA BIO, INC..
“On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the “Board”) notification of her resignation from the Board of FibroGen, effective June 4, 2025.”
Michael Kauffman was appointed as Class III director at KYNTRA BIO, INC..
“Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company.”
KYNTRA BIO, INC.: Amended bylaws to reduce stockholder meeting quorum requirement from a majority to at least one-third of outstanding shares entitled to vote (effective 2025-04-02).
“On April 2, 2025, the board of directors of FibroGen, Inc. (the “Company”) amended and restated the Company’s amended and restated bylaws (as amended and restated, the “Amended and Restated Bylaws”), effective immediately.”
KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“September 12, 2024, FibroGen received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying FibroGen that for 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1) (the “Rule”). Therefore, in accordance with the Nasdaq listing rules, FibroGen was provided 180 calendar days, or until March 11, 2025 to regain compliance with the minimum bid price rule. On March 12, 2025, FibroGen received written noti”
Christine L. Chung departed as Senior Vice President, China Operations at KYNTRA BIO, INC..
“Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us.”
Gerald Lema resigned as Director at KYNTRA BIO, INC..
“On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.”
Benjamin Cravatt resigned as Director at KYNTRA BIO, INC..
“On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.”
Suzanne Blaug resigned as Director at KYNTRA BIO, INC..
“On September 12, 2024, Suzanne Blaug, Benjamin Cravatt, and Gerald Lema each provided to the Board of Directors (the “Board”) notification of their resignations from the Board of FibroGen, Inc. (the “Company”), effective September 30, 2024.”
Deyaa Adib departed as Chief Medical Officer at KYNTRA BIO, INC..
“the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.”
Juan Graham departed as Chief Financial Officer at KYNTRA BIO, INC..
“the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.”
KYNTRA BIO, INC. announced a restructuring with charges of $16-18 million affecting U.S. workforce (approximately 75% with 127 U.S. employees).
“in the progress we have made, and continue to make, in science and the biotechnology industry. The Company estimates that it will incur non-recurring charges in the range of $16-18 million in connection with the Plan, primarily consisting of severance payments, notice pay, accrued vacation, payroll tax and employee benefits contributions. The Company”
KYNTRA BIO, INC. reported 2024 results: revenue between $120 million to $135 million. Guidance reaffirmed.
“For 2024, we anticipate FibroGen’s full year net product revenue under U.S. GAAP to range between $120 million to $135 million, representing full year roxadustat net sales in China 1 by FibroGen and the JDE to range between $300 million to $340 million.”
KYNTRA BIO, INC. reported quarter ended December 31, 2023 results: revenue $27.1 million, net income Net loss for the fourth quarter of 2023 was $56.2 million, or $0.57 net loss per basic and diluted share, EPS $0.57 net loss per basic and diluted share.
“full year roxadustat net sales in China 1 by FibroGen and the JDE to range between $300 million to $340 million. Financial: • Total revenue for the fourth quarter of 2023 was $27.1 million, as compared to $34.4 million for the fourth quarter of 2022. Reduction primarily driven by the change in net product revenue assumptions under U.S. GAAP and drug product revenue”
KYNTRA BIO, INC. reported year ended December 31, 2023 results: revenue $147.8 million, net income Net loss for the year was $284.2 million, or $2.92 net loss per basic and diluted share, EPS $2.92 net loss per basic and diluted share.
“2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea • FY 2023 total net revenue of $147.8 million, an increase of 5% year over year • Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 • Successful execution of cost reduction plan; $248.1 million”
KYNTRA BIO, INC. reported third quarter 2023 results: revenue Total revenue for the third quarter of 2023 was $40.1 million, net income Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share, EPS $0.65 net loss per basic and diluted share.
“FibroGen Reports Third Quarter 2023 Financial Results”
KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“October 24, 2023, FibroGen, Inc. (“FibroGen”) received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying FibroGen that for the last 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of FibroGen’s common stock on Nasdaq. In accordance with listing rule 5810(c)(3)(A), FibroGen has 180 calendar days, or until April 22, 2024, to r”
Thane Wettig was appointed as Chief Executive Officer at KYNTRA BIO, INC..
“On October 2, 2023, the Board of Directors (the “Board”) of FibroGen, Inc. (the “Company”) appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.”
Mark Eisner resigned as Chief Medical Officer at KYNTRA BIO, INC..
“On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc. (the "Company"), effective September 8, 2023, to pursue other opportunities.”
KYNTRA BIO, INC. reported second quarter 2023 results: revenue $44.3 million, net income $87.7 million, EPS $0.90 net loss per basic and diluted share.
“the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024. Financial: • Total revenue for the second quarter of 2023 was $44.3 million, as compared to $29.8 million for the second quarter of 2022, an increase of 49%. • Net loss for the second quarter of 2023 was $87.7 million, or $0.90 net loss per basic and”
Enrique Conterno resigned as Chief Executive Officer at KYNTRA BIO, INC..
“He succeeds Enrique Conterno, who has resigned as Chief Executive Officer and from the Board, and who will remain with the Company as Special Advisor to the Interim CEO through August 8, 2023.”
Thane Wettig was appointed as Interim Chief Executive Officer at KYNTRA BIO, INC..
“the Board of Directors (the "Board") has appointed Thane Wettig, age 58, to the position of Interim Chief Executive Officer (“Interim CEO”), effective July 23, 2023.”
KYNTRA BIO, INC. announced a restructuring with charges of $13-15 million affecting U.S. workforce (approximately 32% (or 104 employees)).
“The Company estimates that it will incur non-recurring charges in the range of $13-15 million in connection with the Plan, primarily consisting of severance payments, notice pay, accrued vacation, and employee benefits contributions.”
KYNTRA BIO, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-07 meeting.
“78,505,537 shares of Common Stock voted for, 674,522 against, and 2,221,103 abstaining.”
KYNTRA BIO, INC. shareholders approved Advisory vote on executive compensation at the 2023-06-07 meeting.
“The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers”
KYNTRA BIO, INC. shareholders approved Election of Class III directors at the 2023-06-07 meeting.
“(i) Enrique Conterno: 67,436,799 shares of Common Stock voted for, 3,332,142 withheld, and 10,632,221 broker non-votes; (ii) Aoife Brennan, M.B., B.Ch.: 69,182,144 shares of Common Stock voted for, 1,586,797 withheld, and 10,632,221 broker non-votes; and (iii) Gerald Lema: 67,636,643 shares of Common Stock voted for, 3,132,298 withheld, and 10,632,221 broker non-votes.”
KYNTRA BIO, INC. reported financial results for the first quarter 2023.
“On May 8, 2023, FibroGen, Inc. (“FibroGen”) issued a press release announcing financial results for the quarter ended March 31, 2023.”
KYNTRA BIO, INC. entered into Financing Agreement with investment funds managed by Morgan Stanley Tactical Value valued at $75,000,000 initial term loan, $37,500,000 delayed draw term loan (effective 2023-04-29).
“On April 29, 2023 (the “ Signing Date ”), FibroGen, Inc. (the “ Company ”) entered into a financing agreement (“ Financing Agreement ”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “ Lenders ”), and Wilmington Trust, National Association, as the administrative agent (the “ Administrative Agent ”), providing for senior secured term loan facilities consisting of (i) a $75,000,000 initial term loan (the “ Initial Term Loan ”), (ii) a $37,500,000 delayed draw term loan that will be funded upon the achievement of certain clinical development milestones (“ Delayed Draw Term Loan 1 ”) and, (iii) an uncommitted delayed draw term loan of up to $37,500,000, to be funded at the Lenders sole discretion, (“ Delayed Draw Term Loan 2 ” and, together with the Initial Term Loan and Delayed Draw Term Loan 1, the “ Term Loans ”).”
KYNTRA BIO, INC. reported the full year 2022 results: revenue $140.7 million, net income $293.7 million net loss, EPS $3.14 net loss per basic and diluted share.
“Total revenue for 2022 was $140.7 million as compared to $235.3 million in 2021, which included $120 million of milestone payments from Astellas related to the EU approval of roxadustat.”
KYNTRA BIO, INC. reported the fourth quarter of 2022 results: revenue $34.4 million, net income $66.2 million net loss, EPS $0.70 net loss per basic and diluted share.
“Total revenue for the fourth quarter of 2022 was $34.4 million, as compared to $16.5 million for the fourth quarter of 2021.”
KYNTRA BIO, INC. reported the third quarter 2022 results: revenue $15.7 million, net income Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share, EPS $0.98 net loss per basic and diluted share.
“Total revenue for the third quarter of 2022 was $15.7 million”
Thomas F. Kearns, Jr. resigned as Director at KYNTRA BIO, INC..
“On June 5, 2022, Thomas F. Kearns, Jr. notified us of his resignation from the Board of Directors (the “Board”) of FibroGen, Inc. (“FibroGen”) effective June 16, 2022.”
Juan Graham was appointed as Chief Financial Officer at KYNTRA BIO, INC..
“the appointment of Juan Graham as CFO, effective September 7, 2021.”
Pat Cotroneo retired as Chief Financial Officer at KYNTRA BIO, INC..
“retirement of Pat Cotroneo as Chief Financial Officer ("CFO")”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.